tiprankstipranks
Capricor Therapeutics (CAPR)
NASDAQ:CAPR
Holding CAPR?
Track your performance easily

Capricor Therapeutics (CAPR) Income Statement

881 Followers

Capricor Therapeutics Income Statement

Last quarter (Q3 2024), Capricor Therapeutics's total revenue was $2.26M, a decrease of -63.44% from the same quarter last year. In Q3, Capricor Therapeutics's net income was $-12.56M. See Capricor Therapeutics’s key income statements, including revenue, expenses, profit, and income.
Income Statement
TTM
Dec 23Dec 22Dec 21Dec 20Dec 19
Total Revenue
$ 23.23M$ 25.18M$ 2.55M$ 244.90K$ 310.25K-
Cost of Revenue
------
Gross Profit
$ 23.23M$ 25.18M$ 2.55M$ 244.90K$ 310.25K-
Operating Expense
$ 59.38M$ 49.26M$ 32.25M$ 21.18M$ 14.00M$ 8.74M
Operating Income
$ -36.15M$ -24.08M$ -29.70M$ -20.94M$ -13.69M$ -8.74M
Net Non Operating Interest Income Expense
------
Other Income Expense
$ 1.55M$ 1.79M$ 677.85K$ -915.92K$ -32.94K$ -1.10M
Pretax Income
$ -34.11M$ -22.29M$ -29.02M$ -20.05M$ -13.70M$ -7.64M
Tax Provision
------
Earnings From Equity Interest Net Of Tax
------
Net Income Common Stockholders
$ -34.11M$ -22.29M$ -29.02M$ -20.02M$ -13.70M$ -7.64M
Basic EPS
$ -1.02$ -0.83$ -1.18$ -0.87$ -0.88-
Diluted EPS
$ -1.02$ -0.83$ -1.18$ -0.87$ -0.88$ -2.06
Basic Average Shares
$ 127.00M$ 26.78M$ 24.55M$ 23.09M$ 15.57M$ 3.71M
Diluted Average Shares
$ 127.00M$ 26.78M$ 24.55M$ 23.09M$ 15.57M$ 3.71M
Dividend Per Share
------
Total Operating Income As Reported
------
Reported Normalized Basic E P S
------
Reported Normalized Diluted E P S
------
Rent Expense Supplemental
------
Total Expenses
$ 59.38M$ 49.26M$ 32.25M$ 21.18M$ 14.00M$ 8.74M
Net Income From Continuing And Discontinued Operation
$ -34.11M$ -22.29M$ -29.02M$ -20.02M$ -13.66M$ -7.64M
Normalized Income
$ -33.57M$ -17.56M-$ -15.83M--
Interest Expense
------
EBIT
$ -34.63M$ -24.08M$ -29.70M$ -20.94M$ -13.69M$ -7.64M
EBITDA
$ -33.27M$ -23.01M$ -29.16M$ -20.69M$ -13.55M$ -7.47M
Currency in USD

Capricor Therapeutics Earnings and Revenue History

What am I Missing?
Make informed decisions based on Top Analysts' activity
Know what industry insiders are buying
Get actionable alerts from top Wall Street Analysts
Find out before anyone else which stock is going to shoot up
Get powerful stock screeners & detailed portfolio analysis